Vertex EVP Bunnage sells 2,021 shares in planned trade

Vertex Pharmaceuticals executive Mark E. Bunnage, EVP and Chief Scientific Officer, reported two transactions in Vertex common stock.

Rhea-AI Filing Summary

Vertex Pharmaceuticals executive Mark E. Bunnage, EVP and Chief Scientific Officer, reported two transactions in Vertex common stock. On February 11, 2026, he made an open-market sale of 2,021 shares at $460.43 per share. On February 10, 2026, 1,127 shares were disposed of at $468.41 per share to cover tax obligations. After these transactions, he directly owns 12,914 shares of Vertex common stock. The filing notes the sale was made under a company-approved Rule 10b5-1 trading plan entered into on November 26, 2025, indicating the trades were pre-scheduled rather than discretionary.

Insights

Equity compensation and insider-trading analyst

Planned insider sale and tax withholding, modest versus typical executive holdings.

The report shows Vertex EVP and Chief Scientific Officer Mark E. Bunnage executing an open-market sale of 2,021 common shares at $460.43, plus a 1,127-share tax-withholding disposition at $468.41. Both positions are reported as directly owned, with 12,914 shares remaining afterward.

The key context is the footnote: the sale occurred under a company-approved Rule 10b5-1 trading plan entered on November 26, 2025. Such plans pre-schedule trades, reducing concerns that the transaction reflects short-term views on Vertex’s prospects. As a result, this looks like routine portfolio and tax management rather than a thesis-changing event.

Insider Trade Summary

Net Seller: 2,021 shares

Net Sell 2 txns

Insider Bunnage Mark E.

Role EVP, Chief Scientific Officer

Sold 2,021 shs ($931K)

Type	Security	Shares	Price	Value
Sale	Common Stock	2,021	$460.43	$931K
Exercise Price or Tax Liability	Common Stock	1,127	$468.41	$528K

Holdings After Transaction: Common Stock — 12,914 shares (Direct)

Footnotes (1)

1. F1. Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transactions did Vertex (VRTX) executive Mark Bunnage report?

Mark E. Bunnage reported selling 2,021 Vertex common shares in an open-market transaction at $460.43 and a separate 1,127-share disposition at $468.41 for tax withholding. After these trades, he directly holds 12,914 Vertex common shares, according to the filing.

Was the Mark Bunnage stock sale at Vertex (VRTX) under a Rule 10b5-1 plan?

Yes. The filing states Dr. Bunnage’s transaction was made under a company-approved Rule 10b5-1 trading plan entered into on November 26, 2025. Such plans pre-arrange trades, suggesting the sale was scheduled rather than based on new, nonpublic information or short-term sentiment.

How many Vertex (VRTX) shares does Mark Bunnage own after these Form 4 transactions?

After the reported transactions, Mark E. Bunnage directly owns 12,914 shares of Vertex Pharmaceuticals common stock. This figure reflects both the 2,021-share open-market sale and the 1,127-share tax-withholding disposition disclosed in the Form 4 insider trading report.

What prices were received in Mark Bunnage’s Vertex (VRTX) stock transactions?

The open-market sale of 2,021 Vertex common shares executed by Mark E. Bunnage was at $460.43 per share. A separate 1,127-share disposition related to tax withholding occurred at $468.41 per share, as detailed in the Form 4 filing for these insider transactions.

What do the transaction codes F and S mean in the Vertex (VRTX) Form 4 for Mark Bunnage?

Code S indicates a sale in the open market or a private transaction, covering the 2,021-share sale at $460.43. Code F reflects a disposition to satisfy tax obligations, explaining the 1,127-share transfer at $468.41 used for tax withholding related to equity compensation.

What is Mark Bunnage’s role at Vertex (VRTX) mentioned in the Form 4 filing?

Mark E. Bunnage is identified as an officer of Vertex Pharmaceuticals, serving as Executive Vice President and Chief Scientific Officer. His leadership role and direct ownership of 12,914 shares after the transactions are both specifically disclosed in the Form 4 insider report.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/12/2026 - 04:56 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bunnage Mark E.

(Last) (First) (Middle)

C/O VERTEX PHARMACEUTICALS INCORPORATED

50 NORTHERN AVENUE

(Street)

BOSTON MA 02210

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
VERTEX PHARMACEUTICALS INC / MA [ VRTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Scientific Officer

3. Date of Earliest Transaction (Month/Day/Year)
02/10/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/10/2026		F		1,127	D	$468.41	14,935	D
Common Stock	02/11/2026		S(1)		2,021	D	$460.43	12,914	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Transaction made pursuant to Dr. Bunnage's company approved trading plan under Rule 10b5-1, which was entered into on 11/26/2025.

Remarks:

	/s/ Christiana Stevenson, Attorney-in-Fact	02/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.